Advances in Dermatology and Allergology
eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current Issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
1/2026
vol. 43
 
Share:
Send email
Share:
Original paper

Analysis of financing of drug programs in allergology in 2020–2024

Krzysztof Nojszewski
1
,
Karina Jahnz-Różyk
2, 3

  1. Novartis Poland
  2. Military Institute of Medicine – National Research Institute, Warsaw, Poland
  3. Department of Internal Diseases, Pneumonology, Allergology, and Clinical Immunology, Military Institute of Medicine, Warsaw, Poland
Adv Dermatol Allergol 2026; XLIII (1): 24-29
DOI: https://doi.org/10.5114/ada.2025.158099
Online publish date: 2026/03/01
Article file
- Analysis.pdf  [0.32 MB]
Get citation
 
 
1. Announcement of the Minister of Health of 20 December 2019 on the list of reimbursed medicines, foodstuffs for particular nutritional uses and medical devices as of 1 January 2020.
2. Announcement of the Minister of Health of 21 December 2020 on the list of reimbursed medicines, foodstuffs for particular nutritional uses and medical devices as of 1 January 2021.
3. Announcement of the Minister of Health of 20 December 2021 on the list of reimbursed medicines, foodstuffs for particular nutritional uses and medical devices as of 1 January 2022.
4. Announcement of the Minister of Health of 21 December 2022 on the list of reimbursed medicines, foodstuffs for particular nutritional uses and medical devices as of 1 January 2023.
5. Announcement of the Minister of Health of 11 December 2023 on the list of reimbursed medicines, foodstuffs for particular nutritional uses and medical devices as of 1 January 2024.
6. Regulation No. 162/2020/DGL of the President of the National Health Fund of 16 October 2020 on specifying the conditions for concluding and implementing contracts for hospital treatment in the scope of/within drug programs.
7. https://stat.gov.pl/obszary-tematyczne/zdrowie/zdrowie/wydatki-na-ochrone-zdrowie-w-latach-2022-2024,27,4.html
8. https://stat.gov.pl/obszary-tematyczne/zdrowie/zdrowie/wydatki-na-ochrone-zdrowie-w-latach-2021-2023,27,4.html
9. Resolution No. 5/2021/IV of the Council of the National Health Fund of 12 March 2021 on the adoption of the annual report on the activities of the National Health Fund for 2020.
10. Resolution No. 3/2022/IV of the Council of the National Health Fund of 16 March 2022 on the adoption of the periodic report on the activities of the National Health Fund for the fourth quarter of 2021.
11. Resolution of the National Health Fund Council Resolution No. 8/2023/IV on the adoption of the periodic report on the activities of the National Health Fund for the fourth quarter of 2022.
12. Resolution No. 5/2024/IV on the adoption of the periodic report on the activities of the National Health Fund for the fourth quarter of 2023.
13. Resolution No. 29/2024/IV of 17 October 2024 on the adoption of the periodic report on the activities of the National Health Fund for the second quarter of 2024.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Termedia.